Join to View Full Profile
1515 Holcombe BlvdUT MD Anderson Cancer Center, Unit 1374Houston, TX 77030
Phone+1 713-792-6161
Dr. Tannir is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Muhlenberg Regional Medical CenterResidency, Internal Medicine, 1984 - 1985
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1981 - 1984
American University of Beirut Faculty of MedicineClass of 1979
Certifications & Licensure
FL State Medical License 2021 - Present
TX State Medical License 1984 - 2027
OK State Medical License 2020 - 2021
KY State Medical License 1987 - 2015
NJ State Medical License 1985 - 1991
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Top Doctors:SE Texas Castle Connolly, 2013
Clinical Trials
- Sunitinib Malate in Patients With Non-Clear Cell Renal Cell Cancer Start of enrollment: 2007 Mar 01
- Pemetrexed Plus Gemcitabine in Renal Cell Cancer Start of enrollment: 2005 Dec 01
- Capecitabine, Gemcitabine, and Bevacizumab in Combination for Patients With Sarcomatoid Renal Cell Carcinoma Start of enrollment: 2007 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- A Call for a Neoadjuvant Kidney Cancer Consortium: Lessons Learned from Other Cancer Types.Axel Bex, Michael Jewett, Bryan Lewis, E Jason Abel, Laurence Albiges
European Urology. 2025-04-01 - 2 citationsClinical Characteristics, Management, and Outcomes of Patients with Renal Medullary Carcinoma: A Single-center Retrospective Analysis of 135 Patients.Justin M Lebenthal, Panayiotis D Kontoyiannis, Andrew W Hahn, Zita D Lim, Priya Rao
European Urology Oncology. 2025-04-01 - TFE3 fusions drive oxidative metabolism and ferroptosis resistance in translocation renal cell carcinoma.Alexandra Helleux, Guillaume Davidson, Antonin Lallement, Fatima Al Hourani, Alexandre Haller
EMBO Molecular Medicine. 2025-03-27
Lectures
- A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with pre...2019 ASCO Annual Meeting - 6/1/2019
- Pegilodecakin with nivolumab (nivo) or pembrolizumab (pembro) in patients (pts) with metastatic renal cell carcinoma (RCC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
- CANTATA: A randomized phase 2 study of CB-839 in combination with cabozantinib vs. placebo with cabozantinib in patients with advanced/metastatic renal cell carcinoma.2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Press Mentions
MD Anderson Research Highlights for February 26, 2025February 26th, 2025- MD Anderson Unveils Groundbreaking Research Breakthroughs – February 26, 2025February 26th, 2025
- CAR T-cell Therapy for Kidney Cancer Builds on Efficacy RecordNovember 9th, 2024
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
